Study on Cytokines in Type 1 Leprosy Reactions

Not yet recruiting

• Conditions: Other forms of leprosy,

• Registration Number: CTRI/2022/03/041539
• Lead Sponsor: ABVIMS and Dr RML Hospital

Brief Summary

To measure the levels of cytokines of Th17 and Treg pathway in skin and blood of patients presenting with type 1 leprosy reactions.

To compare with levels in non reactional leprosy patients

To reassess the levels of the cytokines following resolution of the reaction

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2022-03-28
• Study Start: 2022-08-04

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1.Adult Patients of either sex with Untreated recent Type 1 leprosy reaction, irrespective of MDT status 2.Presence of skin signs of Type 1 Leprosy reaction, with or without neuritis/ nerve function impairment.

Exclusion Criteria

Those already on treatment for Type 1 reaction <18 Years of age Immunosuppressed patients- by way of disease or drugs Pregnancy and lactating females Presence of any other chronic illness.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Levels of cytokine of Th 17 and Treg pathway in skin and blood of patients presenting with Type 1 leprosy reactions	Baeline and after resolution of reaction

Secondary Outcome Measures

Name	Time	Method
To measure levels of cytokines of Th17 and Treg pathway in non reactional leprosy patients	Baseline

Trial Locations

Locations (1)

Dr Ram Manohar Lohia Hospital; 🇮🇳 Central, DELHI, India

Dr Ram Manohar Lohia Hospital

🇮🇳Central, DELHI, India

Dr Srishti Dabas

Principal investigator

8700552041

ssdabass@gmail.com